Clinical trials: psoriasis
Psoriasis
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study uses healthy and psoriasis subjects.
- Trial name
- NCT02303509
- Testing
- UCB5857 Part 1, UCB5857 Part 2
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Psoriasis
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.
- Trial name
- ped PsO rPMS (NCT03925441)
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- AbbVie
Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00645905
- Testing
- adalimumab
- Volunteers
- 148 people
- Sponsor
- Abbott
Scalp Psoriasis
Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
The study will be conducted to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% salicylic acid in octyl-dodecanol with 15% Macrogol-4-laurylether for the removal of scaling in patients…
- Trial name
- NCT01914627
- Testing
- Dimethicone, Salicylic Acid
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- G. Pohl-Boskamp GmbH & Co. KG
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Psoriatic Arthritis
Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis
This is a multicenter, double-blind, randomized, parallel-group study to compare the efficacy,pharmacodynamics (PD), pharmacokinetics (PK), safety, and immunogenicity of BAT2506 versus Simponi® in participants with active PsA.
- Trial name
- NCT05046431
- Testing
- BAT2506, EU Simponi
- Where
- China
- Volunteers
- 704 people
- Sponsor
- Bio-Thera Solutions
Plaque Psoriasis
A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and the preliminary efficacy of AK101，an anti-IL-12/23p40 monoclonal antibody, when administered…
- Trial name
- NCT04172233
- Testing
- AK101
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Akeso
Psoriasis
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
This is a two-part study. The purpose of the pilot study (Part 1) is to optimize the acquisition, handling and shipping procedure for skin biopsies obtained from participants with plaque psoriasis.
- Trial name
- NCT01276847
- Testing
- Ustekinumab, Etanercept
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque…
- Trial name
- SCALP (NCT00669214)
- Testing
- efalizumab
- Volunteers
- 89 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with moderate to severe plaque psoriasis who are…
- Trial name
- NCT00338143
- Testing
- efalizumab
- Volunteers
- 1,200 people
- Sponsor
- Genentech, Inc.
Psoriasis
Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.
- Trial name
- NCT02630901
- Testing
- PRX003
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Prothena Biosciences Limited
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Plaque Psoriasis
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA).
- Trial name
- NCT03764475
- Testing
- Roflumilast
- Where
- 30 sites in United States, Canada
- Volunteers
- 332 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Pruritus, Psoriasis
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis
- Trial name
- NCT03343639
- Testing
- 5 mg Serlopitant Tablets
- Where
- 39 sites in United States
- Volunteers
- 204 people
- Sponsor
- Vyne Therapeutics Inc.
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-2 (NCT01597245)
- Testing
- 80 mg ixekizumab Dosing Regimen, 50 mg etanercept
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 1,224 people
- Sponsor
- Eli Lilly and Company
Arthritis, Psoriatic
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment…
- Trial name
- NCT00090129
- Testing
- Onercept
- Where
- 40 sites in United States, Canada
- Volunteers
- 854 people
- Sponsor
- EMD Serono
Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- EVERLAST-B (NCT07290569)
- Testing
- ORKA-001
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Mild to Moderate Psoriasis, Healthy Volunteers
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.
The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy…
- Trial name
- NCT07849894
- Testing
- UCB0159
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Moderate-to-severe Plaque Psoriasis
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
- Trial name
- NCT07879885
- Testing
- HS-20137
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hansoh BioMedical R&D Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.